Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

NCT05167500 · clinicaltrials.gov ↗

COMPLETED

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG: Lorlatinib

Sponsor

Fundación GECP